PMID- 1665795
OWN - NLM
STAT- MEDLINE
DCOM- 19920415
LR  - 20190624
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 209
IP  - 3
DP  - 1991 Dec 17
TI  - The opioid receptor subtypes mu and kappa, but not delta, are involved in the 
      control of the vasopressin and oxytocin release in the rat.
PG  - 199-206
AB  - The effects of highly selective agonists and antagonists to the mu-, delta- and 
      kappa-opioid receptor subtypes were studied on the vasopressin and oxytocin 
      release in 24 h water-deprived male rats. The delta-agonist 
      [D-Pen2,D-Pen5]enkephalin (dose range 0.01-5 mg/kg) did not affect plasma levels 
      of either hormone 30 min after s.c. administration, whereas the mu-agonist DALDA 
      (H-Tyr-D-Arg-Phe-Lys-NH2) over the same dose range strongly inhibited the release 
      of both vasopressin and oxytocin, an effect that was maximal 30-60 min after s.c. 
      injection. The same effect was found for s.c. administration of the kappa-agonist 
      U-69,593. Intracerebroventricular (i.c.v.) administration of DALDA (0.5 and 5 
      micrograms/kg) but not U-69,593 suppressed both plasma hormone levels 30 min 
      after injection. Also the effects of selective antagonists were tested over the 
      s.c. dose range of 0.01-1 mg/kg. Whereas both the kappa-selective antagonist 
      nor-binaltorphimine and the relatively mu-selective antagonist naloxone elevated 
      oxytocin plasma levels (peak at 15 and 30 min after injection, respectively), the 
      delta-selective antagonist naltrindole was without any effect. 
      Nor-binaltorphimine, naloxone, and naltrindole did not affect vasopressin 
      release. When the antagonists were administered i.c.v. (dose range 2.5-25 
      micrograms/kg), only the kappa-antagonist nor-binaltorphimine enhanced oxytocin 
      and vasopressin release 30 min after injection. In conclusion, both mu- and 
      kappa-opioid receptors are involved in the regulation of the secretion of 
      vasopressin and oxytocin from the rat neural lobe; in contrast, delta-opioid 
      receptors do not play a role.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Van de Heijning, B J
AU  - Van de Heijning BJ
AD  - Department of Medical Pharmacology, University of Utrecht, The Netherlands.
FAU - Koekkoek-Van den Herik, I
AU  - Koekkoek-Van den Herik I
FAU - Van Wimersma Greidanus, T B
AU  - Van Wimersma Greidanus TB
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Receptors, Opioid)
RN  - 0 (Receptors, Opioid, delta)
RN  - 0 (Receptors, Opioid, kappa)
RN  - 0 (Receptors, Opioid, mu)
RN  - 11000-17-2 (Vasopressins)
RN  - 50-56-6 (Oxytocin)
SB  - IM
MH  - Animals
MH  - Male
MH  - Narcotic Antagonists
MH  - Oxytocin/blood/*metabolism
MH  - Radioimmunoassay
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptors, Opioid/drug effects/*physiology
MH  - Receptors, Opioid, delta
MH  - Receptors, Opioid, kappa
MH  - Receptors, Opioid, mu
MH  - Vasopressins/blood/*metabolism
EDAT- 1991/12/17 00:00
MHDA- 1991/12/17 00:01
CRDT- 1991/12/17 00:00
PHST- 1991/12/17 00:00 [pubmed]
PHST- 1991/12/17 00:01 [medline]
PHST- 1991/12/17 00:00 [entrez]
AID - 0014-2999(91)90170-U [pii]
AID - 10.1016/0014-2999(91)90170-u [doi]
PST - ppublish
SO  - Eur J Pharmacol. 1991 Dec 17;209(3):199-206. doi: 10.1016/0014-2999(91)90170-u.